ALDX - Aldeyra Therapeutics, Inc.
| Previous Close | 8.05 |
| Open | 8.10 |
| Bid | 5.50 x 1200 |
| Ask | 15.00 x 1300 |
| Day's Range | 8.05 - 8.60 |
| 52 Week Range | 5.55 - 9.30 |
| Volume | 259,643 |
| Avg. Volume | 106,129 |
| Market Cap | 178.287M |
| Beta | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.58 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.00 |
- Zacks•15 days ago
Implied Volatility Surging for Aldeyra Therapeutics (ALDX) Stock Options
Aldeyra Therapeutics (ALDX) needs investors to pay close attention to the stock based on moves in the options market lately.
- GlobeNewswire•last month
Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx — Fundamental Analysis, Key Performance Indications
NEW YORK, Aug. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PDF ...
- PR Newswire•last month
Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Phase 2b Results for Topical Ocular Reproxalap in Dry Eye Disease Expected in Late Third Quarter or Early Fourth Quarter 2018 Clinical Results from Investigator-Sponsored Trial of ADX-1612 in Mesothelioma ...
- ACCESSWIRE•last month
Aldeyra Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Aldeyra Therapeutics, Inc. (NASDAQ: ALDX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:00 AM Eastern ...
- PR Newswire•2 months ago
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2018 Financial Results and Corporate Update
LEXINGTON, Mass. , Aug. 2, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients ...
- PR Newswire•2 months ago
Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference
LEXINGTON, Mass. , Aug. 1, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...
- PR Newswire•2 months ago
Aldeyra Therapeutics Appoints Joshua Reed as Chief Financial Officer
LEXINGTON, Mass., July 31, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced the appointment of Joshua Reed as Chief Financial Officer. Mr. Reed will succeed Stephen Tulipano, the Company's outgoing Chief Financial Officer. "Aldeyra is an exciting company with a novel and broad pipeline of potentially disruptive clinical product candidates," said Joshua Reed.
- PR Newswire•2 months ago
Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial
LEXINGTON, Mass., July 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the first patient has enrolled in a pivotal Phase 3 clinical trial of topical dermal reproxalap for the treatment of ichthyosis (scaly, thickened, dry skin) associated with Sjögren-Larsson Syndrome (SLS). In August 2016, Aldeyra announced that the results of a randomized, parallel-group, double-blind, vehicle-controlled clinical trial in SLS demonstrated clinically relevant activity in diminishing the severity of ichthyosis.
Market Realist•2 months agoWhy Reata Pharmaceuticals’ Stock Price Is Skyrocketing Today
Today, Reata Pharmaceuticals is trading at a stock price of $75.00, which represents a ~61.67% hike from yesterday’s close of $46.4. On July 20, Reata Pharmaceuticals closed at $46.4, which represents ~140% growth from its 52-week low of $19.31 on March 29. Also today, Reata Pharmaceuticals hit a 52-week high of $76.25.
- PR Newswire•2 months ago
Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial
LEXINGTON, Mass., July 12, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced that the last patient has completed dosing in Aldeyra's randomized, double-masked, vehicle-controlled, multi-center, parallel-group Phase 2b clinical trial of topical ocular reproxalap in dry eye disease. "Dry eye disease, a persistently disturbing ocular inflammatory condition, represents one of the largest ophthalmic markets worldwide," commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "Based on the positive results of our Phase 2a dry eye disease clinical trial, as well as our Phase 2 clinical successes in other ocular inflammatory disorders, we are pleased to complete dosing in our Phase 2b dry eye disease trial, which is designed to establish the drug concentration and patient group sizes for Phase 3 testing.
- PR Newswire•3 months ago
Aldeyra Therapeutics Announces Development Programs at 2018 Research Day
LEXINGTON, Mass., June 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to the development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced product development programs in systemic inflammatory disease, retinal disease, and cancer at the company's 2018 Research Day. "Complementing our late-stage product candidate reproxalap, we have continued to execute on our mission of expanding our pipeline across multiple mechanisms of action and multiple molecular compositions," commented Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra.
- PR Newswire•3 months ago
Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes
LEXINGTON, Mass. , June 25, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...
- PR Newswire•3 months ago
Aldeyra Therapeutics Announces 2018 Research Day
LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...
- PR Newswire•4 months ago
Aldeyra Therapeutics Announces First Quarter 2018 Financial Results
LEXINGTON, Mass. , May 15, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...
- ACCESSWIRE•4 months ago
Aldeyra Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Aldeyra Therapeutics, Inc. (NASDAQ: ALDX ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 15, 2018 at 8:00 AM Eastern Time. ...
- PR Newswire•4 months ago
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
LEXINGTON, Mass., May 10, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced the hiring of David McMullin to the newly created position of Senior Vice President, Corporate Development and Strategy. Mr. McMullin will be responsible for leading Aldeyra's commercial planning, corporate development, and business development efforts. Mr. McMullin brings extensive experience leading business development, strategic planning, commercial and operational activities in the biopharmaceutical industry.
- PR Newswire•4 months ago
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results
LEXINGTON, Mass. , May 9, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients ...
- PR Newswire•5 months ago
Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting
LEXINGTON, Mass., May 1, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, presented the results of a randomized, double-masked, parallel-group Phase 2a dry eye disease clinical trial of topical ocular reproxalap at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting. The primary objective of the trial, to select a formulation for Phase 2b clinical testing, was achieved with the advancement of 0.1% reproxalap. Relative to baseline, dry eye disease patients treated with 0.1% reproxalap demonstrated statistically significant improvement from baseline in tear volume (Schirmer test) as well as statistically and clinically significant improvement in the Overall 4-Symptom Score and the Ocular Discomfort Score.
- PR Newswire•5 months ago
Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
LEXINGTON, Mass., April 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has enrolled the first patient in a Phase 3 clinical trial of topical ocular reproxalap for the treatment of allergic conjunctivitis. "We are pleased to advance our allergic conjunctivitis program to Phase 3 clinical testing," commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "With clinically demonstrated post-histaminic activity, reproxalap could represent the first mechanistically differentiated product in decades for the treatment of allergic conjunctivitis, a chronic disease that affects approximately 100 million patients in the United States.
- ACCESSWIRE•5 months ago
Free Post Earnings Research Report: Curis’ Quarterly Revenue Jumped 38.10%
Stock Monitor: Aldeyra Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free earnings report on Curis, Inc. (NASDAQ: CRIS ). If you ...
- PR Newswire•6 months ago
Aldeyra Therapeutics Announces Year End 2017 Financial Results
LEXINGTON, Mass. , March 29, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...
- ACCESSWIRE•6 months ago
Aldeyra Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 29, 2018 / Aldeyra Therapeutics, Inc. (NASDAQ: ALDX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 29, 2018 at 8:00 AM Eastern ...
- PR Newswire•6 months ago
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results
LEXINGTON, Mass. , March 22, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...
